Recent recommendations by the US Preventive Task Force on Breast Cancer advising that women under the age of 50 should not get routine mammograms have resulted in fierce debate within the medical community. According to a new oncology study from ORC, an Infogroup Company, 70 percent of oncologists and 60 percent of ob-gyns disagree with the assertion that women should not get mammograms before the age of 50. The prevailing argument against the Task Force’s mammogram recommendation is that too many women under the age of 50 have breast cancer and that it would allow many breast cancer cases to go undetected. ORC’s Oncology Report delved into research analysis on three important Oncology issues: assessing the impact of revised NSCLC staging, genetically linked breast cancer and PARP-1 Inhibitors and Reactions to New Mammogram Recommendations. The mammogram debate was one of a number of key issues covered in ORC’s study, which captured the awareness, perceptions, ideal patient profiles and adoption rates of physicians towards PARP-1 Inhibitors post FDA-approval as a treatment for breast and ovarian cancers. PARP-1 Inhibitors have been widely discussed and exhibit efficacy in clinical trials, but minimal data has been collected so far to gauge their wider acceptance. Fifty percent of medical oncologists and 80 percent of ob-gyns were unable to name any PARP-1 inhibitor without being prompted. “We were initially concerned with the physician’s lack of awareness and information on PARP-1 Inhibitors, since such awareness can help determine therapy and answer important questions about genetically linked breast and ovarian cancer treatment,” said Vaibhav Varkhedkar, Vice President of ORC’s Oncology Practice . “However, based on our data, we are optimistic that the usage of PARP-1 Inhibitors post FDA-approval will grow and eventually become the treatment of choice for certain hard to treat breast and ovarian cancers.” To learn more and to obtain a copy of the full report, visit http://lp.infogroup.com/oncology-report. About our Global Oncology Practice As a dedicated practice within our pharmaceutical business unit, ORC’s oncology team is a well recognized and respected provider of market research solutions spanning a myriad of complex issues in cancer diagnostics and treatment. All of our oncology-based research is anchored in our extensive knowledge of latest cancer epidemiology, disease modalities and marketing implications.
About ORCORC, an Infogroup company, is a leading global market research firm with offices across the U.S., Europe and Asia Pacific region. ORC offers the unique ability to integrate primary and secondary research, competitive intelligence and expert insight to address the business challenges of its clients worldwide. The company has been a partner of CNN on the CNN/Opinion Research Corporation poll since 2006. To learn more about ORC, visit www.opinionresearch.com. About Infogroup Infogroup (NASDAQ: IUSA) is the leading provider of data and interactive resources that enables targeted sales, effective marketing and insightful research solutions. Our information powers innovative tools and insight for businesses to efficiently reach current and future customers through multiple channels, including the world’s most dominant and powerful Internet search engines and GPS navigation systems. Infogroup’s headquarters are located at 5711 South 86 th Circle, Omaha, NE 68127. For more information, call (402) 593-4500 or visit www.infogroup.com. Statements in this announcement other than historical data and information constitute forward looking statements that involve risks and uncertainties that could cause actual results to differ materially from those stated or implied by such forward-looking statements. The potential risks and uncertainties include, but are not limited to, recent changes in senior management, the successful integration of recent and future acquisitions, fluctuations in operating results, failure to successfully carry out our Internet strategy or to grow our Internet revenue, effects of leverage, changes in technology and increased competition. More information about potential factors that could affect the company’s business and financial results is included in the company’s filings with the Securities and Exchange Commission.